EDAP Continues Worldwide Ablatherm Marketing and Education; Conference Participation Increasing Awareness in Medical Community;

LYON, France, Sept. 7  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), the world leader in High Intensity Focused Ultrasound treatment of localized prostate cancer, is pleased to report continued success in market education through participation in multiple medical congresses and events.

On August 23-26, EDAP participated in the 23rd World Congress of Endourology (W.C.E.), held in Amsterdam, The Netherlands.  Six abstracts were presented by Dr. Albert Gelet and Dr. Stefan Thuroff describing Ablatherm-HIFU experience and treatment outcomes on patients who were not candidates for surgery or who failed radiotherapy.  Pr. Christian Chaussy, a highly experienced Ablatherm practitioner moderated a HIFU discussion session for interested physicians.  Dr. Thuroff presented a study on 1,200 HIFU treatments performed over 8 years that confirmed the minimal side effects related to Ablatherm-HIFU treatments and the exclusion of any severe systematic side effects.  Dr. Thuroff also presented a study at 5-6 years based on 1,000 treatments performed using curative HIFU showing a negative biopsy rate up to 93%.  The study also presented the use of a nerve sparing technique, which allows urologists to preserve potency in 70% of cases.  Dr. Gelet presented two abstracts related to the evaluation of efficacy, safety and tolerance of HIFU treatment after external beam radiation failures at 2 years.  The study shows an 84% negative biopsy rate and related side effects much lower than those reported after all types of other salvage therapies.  Ablatherm-HIFU remains unique among treatment options for localized prostate cancer due to its applicability to patients who have limited treatment options for reasons of health, failed prior treatments or other medical and lifestyle concerns.

Dr. Thuroff also hosted an educational course about Ablatherm-HIFU for urologists seeking to learn about the treatment methodology for their local clinical settings.  The EDAP booth received a steady stream of inquiries about the procedure and requests for reference material.  Of particular interest to urologists attending from Italy and the United Kingdom were existing treatment centers in their home countries with experienced practitioners.  Acceptance of Ablatherm-HIFU as a mainstream treatment option has been expanding throughout Europe due to EDAP's strong history of clinical success and extensive physician-directed training programs.  Additionally, Ablatherm-HIFU is a reimbursable treatment in Italy and will soon obtain reimbursement in the U.K.

EDAP plans to address the German urology community, where the company has already established Ablatherm-HIFU as a successful treatment choice through the use of its mobile per-procedure business model, by participation at the upcoming Deutsche Gesellschaft fur Urologie (DGU) to be held in Dusseldorf September 21 - 24.  EDAP will be actively promoting Ablatherm-HIFU information as well as organizing "meet-the-expert" meetings on its booth.  EDAP recently reported annualized growth rates of its mobile business in excess of 70% for German markets as well as the addition of a second mobile Ablatherm unit to meet increasing demand for the treatment.

EDAP will attend the Societe International d'Urologie (SIU) Meeting on Prostatic Disease September 29-October 1, 2005 in Bariloche, Argentina.  The Scientific Program will focus on recent advances and new technologies in treating prostate diseases, including Ablatherm HIFU.  Dr. Chris D'Hont, from AZ Middelheim in Antwerpen, Belgium, will share his four years of experience on the use of Ablatherm-HIFU and present a summary of clinical results demonstrating the treatment's history of successful outcomes with low associated side effects and outlining the second chance offered by Ablatherm for patients who failed external beam therapy.

Finally, EDAP will participate in the 5th International Society on Therapeutic Ultrasound meeting to be held in Boston, USA, October 27-29, 2005. Founded in 2001, the organization represents the growing interest in therapeutic ultrasound in general and HIFU in particular.  The ISTU gathers international representatives of the medical, scientific and educational communities to assess the current leading edge in therapeutic ultrasound, and to share insights among researchers, clinical users and device manufacturers. EDAP, together with its Research partner INSERM, will present its latest studies and progress on HIFU.

Hugues de Bantel, EDAP's Chief Executive Officer, commented:  "We remain confident in our European growth through established programs like those in Italy, France and Germany as well as the pending reimbursement in the U.K. which will further advance our market opportunity.  By focusing our marketing efforts on physicians, we continue to build increasing demand for the Ablatherm-HIFU treatment, which we fulfill primarily through the application of mobile per-procedure access to the equipment.  Our extensive clinical data and clear dedication to maintaining our position as the technical and clinical leader in HIFU for localized prostate cancer are clearly important elements as more physicians choose to recommend the procedure to their patients."

Additionally, September has been designated Prostate Cancer Awareness month on a permanent basis in the United States, furthering awareness and focus on prostate cancer.  A number of events and awareness programs are being planned nationwide to spread information about prostate disease.  Ablatherm availability in North America through the Toronto clinic location was discussed in the September 2005 edition of Us TOO Prostate Cancer Education and Support Hotsheet.  The article summarized a number of Ablatherm findings including the high success rate with minimal side effects and repeatability. The Us TOO International Prostate Cancer Education and Support Network is a nonprofit, grassroots organization for prostate cancer patients, survivors, their spouses/partners and families and will be involved in a number of activities during the September awareness efforts.

"Increasing awareness and early detection are helping more men identify prostate disease and seek treatment more quickly," commented de Bantel.  "This will continue to increase demand for less invasive treatment options that have smaller side effect impacts on the patient's lifestyle.  We remain committed to the North American market as an additional opportunity beyond our present success in Europe."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer.  HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.  The company is also developing this technology for the treatment of certain other types of tumors.  EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by phone at [phone] or see the Company's Web site at: http://www.edap-tms.com/ .

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties.  These include statements regarding the Company's growth and expansion plans.  Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.

   CONTACT:  EDAP TMS S.A.
             Hugues de Bantel - Philippe Chauveau
             Blandine Confort
             [phone]

             Halliburton Investor Relations
             Matt Kreps - Geralyn DeBusk
             972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all

of EDAP TMS S.A., [phone]; or Matt Kreps, or Geralyn DeBusk, both of

Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/ 

Copyright